Meeting
2024 ASCO Genitourinary Cancers Symposium
Validity of renal function eligibility criteria for cisplatin-based chemotherapy for patients with urothelial carcinoma.
Authors
Sai Hi
Nagoya University Graduate School of Medicine, Nagoya, Japan
Sai Hi , Yushi Naito , Kyosuke Hattori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 638)
DOI
10.1200/JCO.2024.42.4_suppl.638
Abstract #
638
Poster Bd #
J2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.
First Author: Evangelia Vlachou
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
First Author: Daniela V. Castro
Poster
2022 ASCO Annual Meeting
Impact of adverse health outcomes (AHOs) on self-reported physical and mental health in U.S. testicular cancer survivors (TCS).
First Author: Paul C. Dinh Jr.